Guggenheim Reiterates Neutral on SpringWorks Therapeutics, Maintains $47 Price Target

Benzinga · 05/12/2025 14:07
Guggenheim analyst Michael Schmidt reiterates SpringWorks Therapeutics (NASDAQ:SWTX) with a Neutral and maintains $47 price target.